Abstract
Caspofungin inhibits the synthesis of 1,3-beta-D-glucan, a key step in fungal cell wall biosynthesis. Here we report on its potent in vitro activity (MIC at which 90% of the isolates tested are inhibited = 1 microg per ml of RPMI medium) against 32 Candida albicans fluconazole-susceptible and -resistant clinical isolates irrespective of the underlying resistance mechanism (alterations in ERG11 and/or upregulation of MDR and CDR genes encoding efflux pumps) and provide further evidence that caspofungin is not a substrate for multidrug transporters.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
AIDS-Related Opportunistic Infections / microbiology
-
Anti-Bacterial Agents / pharmacology*
-
Antifungal Agents / pharmacology*
-
Azoles / pharmacology*
-
Candida albicans / drug effects*
-
Candidiasis, Oral / microbiology
-
Caspofungin
-
Drug Resistance, Fungal* / genetics
-
Echinocandins
-
Fluconazole / pharmacology
-
Fungal Proteins / genetics
-
Humans
-
Lipopeptides
-
Microbial Sensitivity Tests
-
Peptides*
-
Peptides, Cyclic*
Substances
-
Anti-Bacterial Agents
-
Antifungal Agents
-
Azoles
-
Echinocandins
-
Fungal Proteins
-
Lipopeptides
-
Peptides
-
Peptides, Cyclic
-
Fluconazole
-
Caspofungin